Odonate, Inc.

ODT

US6760793041

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 16:30:48 2024-05-09 EDT			5-day change	1st Jan Change
2,850 ^USD	-83.34%		0.00%	-81.00%

2023	North American Morning Briefing : Recession Threat Grows as Further Tightening Likely	DJ
2023	North American Morning Briefing : Stock Futures -2-	DJ

Odonate Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020

April 28, 2020 at 08:03 am

Odonate Therapeutics, Inc. announced earnings results for the first quarter ended March 31, 2020. For the first quarter, the company announced operating loss was USD 30.821 million compared to USD 29.222 million a year ago. Net loss was USD 30.163 million compared to USD 28.645 million a year ago. Basic loss per share from continuing operations was USD 0.99 compared to USD 1.16 a year ago.

Latest news about Odonate, Inc.

North American Morning Briefing : Recession Threat Grows as Further Tightening Likely	23-06-23	DJ
North American Morning Briefing : Stock Futures -2-	23-06-16	DJ
North American Morning Briefing : Caution Ahead of Fed, Inflation Data to Hold Back Stocks	23-06-09	DJ
North American Morning Briefing : Stock Futures -2-	23-06-02	DJ
North American Morning Briefing : Investors Await -2-	23-05-26	DJ
North American Morning Briefing : Powell on Tap -2-	23-05-19	DJ
North American Morning Briefing : Hopes of Easing -2-	23-05-12	DJ
North American Morning Briefing : Caution -2-	23-04-14	DJ
North American Morning Briefing : Stock Futures -2-	22-05-20	DJ
North American Morning Briefing : Tech Futures -2-	22-05-13	DJ
North American Morning Briefing : Stocks Waver, -3-	22-04-12	DJ
North American Morning Briefing : Stocks to Open -3-	22-02-22	DJ
Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from S&P Global BMI Index	22-01-20	CI
Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from S&P TMI Index	22-01-20	CI
Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from NASDAQ Composite Index	22-01-17	CI
Top Midday Decliners	22-01-07	MT
Odonate Therapeutics Gets Nasdaq Notice to Delist Shares	22-01-07	MT
Odonate Therapeutics, Inc.(NasdaqGS:ODT) dropped from NASDAQ Biotechnology Index	21-12-17	CI
Insider Sell: Odonate Therapeutics	21-11-22	MT
Odonate Therapeutics Plans Share Buybacks After Halting Development of Breast Cancer Drug	21-11-17	MT
Odonate Therapeutics, Inc. announces an Equity Buyback for 20,000,000 shares, representing 51.95% of its issued share capital.	21-11-17	CI
Odonate Therapeutics, Inc. authorizes a Buyback Plan.	21-11-16	CI
Odonate Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-10	CI
North American Morning Briefing : Stock Futures -3-	21-11-10	DJ
Odonate Therapeutics, Inc. Announces Termination of Joseph O’Connell as Chief Medical Officer	21-08-05	CI

Chart Odonate, Inc.

Duration

Period

More charts

Company Profile

Odonate, Inc., formerly Odonate Therapeutics, Inc., is a pharmaceutical company. The Company is focused on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The Company is no longer in development of tesetax.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ODONATE, INC.	-81.00%	8.09M
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+33.05%	599B
JOHNSON & JOHNSON	-6.23%	354B
MERCK & CO., INC.	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+16.00%	243B
NOVARTIS AG	+8.09%	205B
ROCHE HOLDING AG	-5.77%	203B
AMGEN INC.	+6.19%	164B

Other Pharmaceuticals

Odonate, Inc.

Equities

ODT

US6760793041

Pharmaceuticals

Odonate Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020

Latest news about Odonate, Inc.

Chart Odonate, Inc.

Company Profile

Sector Other Pharmaceuticals